Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression
- The University of Cambridge Metabolic Research Laboratories, United Kingdom
- University of Pavia, Italy
- University of Birmingham, United Kingdom
- Aarhus University Hospital, Denmark
- UCB Pharma, United Kingdom
- Wellcome Trust Sanger Institute, United Kingdom
- University of Cambridge School of Clinical Medicine, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust, United Kingdom
- University of Copenhagen, Denmark
- Birmingham Women's Hospital, United Kingdom
- UCL Institute of Neurology, United Kingdom
- National Institutes of Health, United States
- University of Maryland School of Medicine, United States
- Brehm Center for Diabetes, United States
- The National Institute for Health Research Cambridge Biomedical Research Centre, United Kingdom
- Aarhus University, Denmark
Abstract
MFN2 encodes mitofusin 2, a membrane-bound mediator of mitochondrial membrane fusion and inter-organelle communication. MFN2 mutations cause axonal neuropathy, with associated lipodystrophy only occasionally noted, however homozygosity for the p.Arg707Trp mutation was recently associated with upper body adipose overgrowth. We describe similar massive adipose overgrowth with suppressed leptin expression in four further patients with biallelic MFN2 mutations and at least one p.Arg707Trp allele. Overgrown tissue was composed of normal-sized, UCP1-negative unilocular adipocytes, with mitochondrial network fragmentation, disorganised cristae, and increased autophagosomes. There was strong transcriptional evidence of mitochondrial stress signalling, increased protein synthesis, and suppression of signatures of cell death in affected tissue, whereas mitochondrial morphology and gene expression were normal in skin fibroblasts. These findings suggest that specific MFN2 mutations cause tissue-selective mitochondrial dysfunction with increased adipocyte proliferation and survival, confirm a novel form of excess adiposity with paradoxical suppression of leptin expression, and suggest potential targeted therapies.
Data availability
-
RNA-seq of overgrown interscapular adipose tissue with biallelic MFN2 mutationsPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE97156).
-
ClinVar: public archive of interpretations of clinically relevant variantsPublicly available at the NCBI ClinVar (accession no: RCV000002369).
-
Exome Aggregation Consortium (ExAC)Publicly available at Broad Institute (accession no: ENSG00000116688).
Article and author information
Author details
Funding
Medical Research Council (MRC_MC_UU_12012/5)
- Nuno M Rocha
Wellcome (Wellcome Trust Postdoctoral Fellowship for Clinicians (10043/Z/15/Z))
- Alex Rossor
National Institute for Health Research (NIHR Clinical Research Facilities for Experimental Medicine Award to Cambridge NIHR/Wellcome Trust)
- Alison Sleigh
National Institute for Health Research (Cambridge BRC and Clinical Research Facility; Rare Disease Translational Research Collaboration)
- Stephen I O'Rahilly
- Eamonn R Maher
- David B Savage
- Robert K Semple
National Institutes of Health (Oxford-Cambridge Scholars Programme)
- David A Bulger
Wellcome (WT098051)
- Felicity Payne
- Inês Barroso
National Institute of Diabetes and Digestive and Kidney Diseases (Intramural research program)
- Elif A Oral
National Institute of Diabetes and Digestive and Kidney Diseases (RO1-DK 08811)
- Elif A Oral
UCB Pharma (Gen 001)
- Hannah Titheradge
- Duncan McHale
- Eamonn R Maher
Medical Research Council (MRC Centre grant (G0601943))
- Mary Reilly
National Institutes of Neurological Diseases and Stroke and office of Rare Diseases (U54NS065712)
- Mary Reilly
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: Written informed consent was obtained from all participants or their parents if under 18 years old for the research described and for publication of results. The research was approved by the Cambridgeshire South Research Ethics Committee, Reference no. 12/EE/0405
Copyright
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Metrics
-
- 3,623
- views
-
- 806
- downloads
-
- 67
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression
eLife 6:e23813.
https://doi.org/10.7554/eLife.23813
Further reading
-
- Cell Biology
- Chromosomes and Gene Expression
Meiotic crossover recombination is essential for both accurate chromosome segregation and the generation of new haplotypes for natural selection to act upon. This requirement is known as crossover assurance and is one example of crossover control. While the conserved role of the ATPase, PCH-2, during meiotic prophase has been enigmatic, a universal phenotype when pch-2 or its orthologs are mutated is a change in the number and distribution of meiotic crossovers. Here, we show that PCH-2 controls the number and distribution of crossovers by antagonizing their formation. This antagonism produces different effects at different stages of meiotic prophase: early in meiotic prophase, PCH-2 prevents double-strand breaks from becoming crossover-eligible intermediates, limiting crossover formation at sites of initial double-strand break formation and homolog interactions. Later in meiotic prophase, PCH-2 winnows the number of crossover-eligible intermediates, contributing to the designation of crossovers and ultimately, crossover assurance. We also demonstrate that PCH-2 accomplishes this regulation through the meiotic HORMAD, HIM-3. Our data strongly support a model in which PCH-2’s conserved role is to remodel meiotic HORMADs throughout meiotic prophase to destabilize crossover-eligible precursors and coordinate meiotic recombination with synapsis, ensuring the progressive implementation of meiotic recombination and explaining its function in the pachytene checkpoint and crossover control.
-
- Cell Biology
In animals, mitosis involves the breakdown of the nucleus. The reassembly of a nucleus after mitosis requires the reformation of the nuclear envelope around a single mass of chromosomes. This process requires Ankle2 (also known as LEM4 in humans) which interacts with PP2A and promotes the function of the Barrier-to-Autointegration Factor (BAF). Upon dephosphorylation, BAF dimers cross-bridge chromosomes and bind lamins and transmembrane proteins of the reassembling nuclear envelope. How Ankle2 functions in mitosis is incompletely understood. Using a combination of approaches in Drosophila, along with structural modeling, we provide several lines of evidence that suggest that Ankle2 is a regulatory subunit of PP2A, explaining how it promotes BAF dephosphorylation. In addition, we discovered that Ankle2 interacts with the endoplasmic reticulum protein Vap33, which is required for Ankle2 localization at the reassembling nuclear envelope during telophase. We identified the interaction sites of PP2A and Vap33 on Ankle2. Through genetic rescue experiments, we show that the Ankle2/PP2A interaction is essential for the function of Ankle2 in nuclear reassembly and that the Ankle2/Vap33 interaction also promotes this process. Our study sheds light on the molecular mechanisms of post-mitotic nuclear reassembly and suggests that the endoplasmic reticulum is not merely a source of membranes in the process, but also provides localized enzymatic activity.
